Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedPage revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedPublication citation updated: added Lancet Oncology 2025 paper on MIRASOL patient-reported outcomes with an erratum; the previous v3.4.2 citation was removed.SummaryDifference0.0%

- Check50 days agoChange DetectedAdded Fallopian tube cancer as a listed condition on the study page and updated the page revision to v3.4.2.SummaryDifference0.0%

- Check57 days agoChange DetectedMinor site maintenance: Revision: v3.4.1 added and Revision: v3.4.0 removed; no effect on study details or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check72 days agoChange DetectedThis update adds a glossary toggle and updates certain metadata labels (Last Update Submitted that Met QC Criteria, Last Update Posted) and the revision to v3.4.0, with minor labeling adjustments for No FEAR Act data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check79 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.